Long-Term Efficacy of Atenolol for Atrioventricular Reciprocating Tachycardia in Children Less Than 5 Years Old

Pediatric Cardiology

Volumn 25, Issue 2, 2004, Pages 97-101

  Ko, J K ^a   Ban, J E ^a   Kim, Y H ^a   Park, I S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Atenolol; Atrioventricular reciprocating tachycardia; Children

Indexed keywords

AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; SOTALOL;

AGE; ARTICLE; ATRIOVENTRICULAR RECIPROCATING TACHYCARDIA; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFANT; LONG TERM CARE; MALE; MONOTHERAPY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATENOLOL; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT WELFARE; KOREA; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SOTALOL; TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY; TACHYCARDIA, PAROXYSMAL; TIME; TREATMENT OUTCOME;

EID: 1342329577     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-003-0536-x     Document Type: Article

References (16)

1. Ko JK, Deal BJ, Strasburger JF, Benson Jr DW (1992) Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 69:1028-1032
2. Friedman RA, Walsh EP, Silka MJ, Calkins H, Stevenson WG, Rhodes LA, Deal BJ, Wolff GS, Demaso DG, Hanisch D, Van Hare GF (2002) NASPE Expert Consensus Conference: Radiofrequency Catheter Ablation in Children with and without Congenital Heart Disease. Report of the Writing Committee. PACE 25:1000-1017
3. Kugler JD, Danford DA (1996) Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 129:324-338
4. Bausersfeld U, Pfammatter JP, Jaeggi E (2000) Treatment of supraventricular tachycardias in the new millennium-Drugs or radiofrequency catheter ablation. Eur J Pediatr 160:1-9
5. Garson Jr A, Gillette PC, McNamara DG (1981) Supraventricular tachycardia in children: Clinical features, response to treatment, and long-term follow-up in 217 patients. J Pediatr 98:875-882
6. Deal BJ, Keane JF, Gillette PC, Garson Jr A (1985) Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up. J Am Coll Cardiol 5:130-135
7. Benson Jr DW, Dunningan A, Benditt DG (1987) Follow-up evaluation of infant paroxyamal atrial tachycardia: Transesophageal study. Circulation 75:542-549
8. Perry JC, Garson Jr A (1990) Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: Early disappearance and late recurrence. J Am Coll Cardiol 16:1215-1220
9. Lindsay BD, Saksena S, Rothbart ST, Herman S, Barr MJ (1987) Long-term efficacy and safety of beta-adrenergic receptor antagonists for supraventricular tachycardia. Am J Cardiol 60:63D-67D
10. Trippel DL, Gillette PC (1989) Atenolol in children with supraventricular tachycardia. Am J Cardiol 64:233-236
11. Mehta AV, Subrahmanyam AB, Anand R (1996) Long-term efficacy and safety of atenolol for supraventricular tachycardia in children. Pediatr Cardiol 17:231-236
12. Gallagher JJ, Kasell J, Smith WM, Grant AO, Benson Jr DW (1980) Use of the esophageal lead in the diagnosis of mechanisms of reciprocating supraventricular tachycardia. PACE 3:440-451
13. Weindling SN, Saul JP, Walsh EP (1996) Efficacy and risk of medical therapy for supraventricular tachycardia in neonates and infants. Am Heart J 131:66-72
14. Haverkamp W, Hindricks G, Güker H (1990) Antiarrhythmic properties β-blockers. J Cardiovasc Pharmacol 16(suppl 5): S29-S32
15. Wadworth AN, Murdoch D, Brogden RN (1991) Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42:468-510
16. McAinsh J, Cruickshank JM (1990) Beta-blockers and central nervous System side effects. Pharmacol Ther 46(2):163-197